This article is more than 5 years old. Information may no longer be current.
Top updates in hormone therapy
Click Here to Manage Email Alerts
Here’s a look at the most popular recent hormone therapy reports at Endocrine Today. Readers were interested in cardiometabolic risks of hormonal contraception as well as FDA approvals for testosterone self-injections and bioidentical hormone therapies for menopausal hot flashes.
Here’s a look at the most popular recent hormone therapy reports at Endocrine Today. Readers were interested in cardiometabolic risks of hormonal contraception as well as FDA approvals for testosterone self-injections and bioidentical hormone therapies for menopausal hot flashes.
Consider cardiometabolic risks when prescribing hormonal contraception
Among the increasing numbers of U.S. women with metabolic syndrome, choice of contraceptive method can influence their risk for cardiovascular disease, according to a presenter at the Cardiometabolic Health Congress.
FDA approves testosterone self-injection for hypogonadism in men
The FDA on Monday approved Antares Pharma’s testosterone enanthate injection Xyosted for testosterone replacement therapy in men with primary hypogonadism or hypogonadotropic hypogonadism, the company announced in a press release.
FDA approves bioidentical hormone therapy for menopausal hot flashes
The FDA has approved the first bioidentical hormone therapy combination of estradiol and progesterone for moderate to severe vasomotor symptoms associated with menopause, TherapeuticsMD announced in a press release.
Physicians hesitant to prescribe vulvar atrophy treatment to breast cancer survivors
OB-GYNs and primary care physicians reported similar attitudes toward treatment for vulvar and vaginal atrophy, or VVA, including a low comfort level when prescribing treatment for the condition to women with a history of breast cancer, according to survey data published in Menopause.
Study used to justify international women’s track and field eligibility rule leaves questions
New track and field regulations from the International Association of Athletics Federations, or IAAF, due to take effect in November will require some female athletes with elevated testosterone levels to medically reduce their testosterone to compete in select events. The regulations specify that the threshold applies only to “relevant females” who have a disorder of sex development, as defined by the organization, testosterone levels of at least 5 nmol/L, and sufficient androgen sensitivity.